Exicure

United States
Victoria, Virginia, United States, 60614

Company profile

Exicure company profile

Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Business identity

Phone number
(847)673-1700
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2009-01-01, Year

Headquarters

Postal code
60614
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
12
Total equity funding
$110.9M
Last funding
Post IPO Equity / $5.4M / 2022-09-26
Last equity funding
Post IPO Equity / $5.4M
Investors
26
Lead investors
3
Founders
1
Articles
138
Exited on
2019-12-19

Founders and investors

Founders

David A. Giljohann

Lead investors

AbbVieCBI USALuye Pharma

Investors

AbbVieAlumni VenturesHercules CapitalInnovation EndeavorsTempus